Opinion

Video

Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Author(s):

Trinity Bivalacqua, MD, PhD,Mark D. Tyson, MD, MPH

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      • In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
      • Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Can ctDNA detect molecular residual disease in NMIBC?
      DNA helix | Image Credit: © Radomir Jovanovic - stock.adobe.com
      Betty Wang, MD, and Laura Bukavina, MD, MPH, MSc, discuss ctDNA's role in NMIBC treatment decisions
      Medical stethoscope and dollar bills | Image Credit: © Kuzmick - stock.adobe.com
      TMT for bladder cancer: Balancing cost and quality of life
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Anne Schuckman, MD, outlines current challenges in NMIBC care
      Daniel D. Joyce, MD, MS, answers a question during a Zoom video interview
      Investigators compare trimodal therapy vs cystectomy in MIBC
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Investigators assess ctDNA’s role in NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
      Urology Times Mitomycin RX Review Square Thumb
      RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
      Related Content
      Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC
      July 21st 2025

      Mitomycin intravesical solution demonstrates long-term durability in LG-IR-NMIBC

      Hannah Clarke
      Mitomycin intravesical solution was granted FDA approval in June 2025 for recurrent LG-IR-NMIBC.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC
      July 17th 2025

      FDA grants priority review to NDA for TAR-200 in BCG-unresponsive NMIBC

      Hannah Clarke
      The new drug application for TAR-200 is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.
      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
      December 7th 2021

      Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

      Urology Times staff
      “It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
      Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC
      July 16th 2025

      Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC

      Hannah Clarke
      Alpha1H was granted a fast track designation in November 2023.
      Data support combination intravesical chemotherapy for high-risk NMIBC
      July 10th 2025

      Data support combination intravesical chemotherapy for high-risk NMIBC

      Hannah Clarke
      “This study adds to the growing body of evidence supporting combination intravesical chemotherapy as a feasible option even after prior treatment failure," says Ian M. McElree, MD.
      © 2025 MJH Life Sciences

      All rights reserved.